CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma.
Platinum-based therapy is most often used to treat advanced cases of head and neck cancers, but only a small fraction of the patient population responds to cisplatin, with a median survival time of less than a year. Although gene signatures and molecular etiology of head and neck cancers have been previously described, none of them are predictive indicators of cisplatin treatment response in particular. Therefore, currently, there is a lack of clinically employable predictive indicators of the disease beyond HPV status to specifically predict patients' response to platinum-based therapy. It beckons a substantial effort to look for predictive indicators of cisplatin treatment response. In this regard, CD24 expression level appears to be a significant molecular phenotype of cisplatin-resistant residual cells in laryngeal carcinoma lines. CD24 expression level directly affects cisplatin sensitivity and affects the expression of critical apoptotic, stem and drug resistance genes. A relatively small retrospective patient tumor analysis suggests that CD24 high tumors go on to show an unfavorable response to cisplatin treatment. Overall, based on the strength of further analysis, CD24 presents a strong rationale to be utilized as a predictive indicator to stratify head and neck cancer patients for platinum-based therapy. It also provides a rationale for using CD24 as a therapeutic adjuvant target along with standard cisplatin therapy.
Department of Medical Microbiology, Immunology and Cell Biology, SIU, Springfield, Illinois, United States of America.
Vishnu
V
Modur
Department of Medical Microbiology, Immunology and Cell Biology, SIU, Springfield, Illinois, United States of America.
Pooja
P
Joshi
Department of Medical Microbiology, Immunology and Cell Biology, SIU, Springfield, Illinois, United States of America.|Southern Illinois University School of Medicine, Springfield, Illinois, United States of America.|Simmons Cancer Institute at SIU, Post Office Box 19678, Springfield, Illinois 62794-9678, United States of America.
Daotai
D
Nie
Division of Hematology and Oncology, Department of Internal Medicine, SIU, Springfield, Illinois, United States of America.|Department of ENT - Otolaryngology, SIU, Springfield, Illinois, United States of America.|Southern Illinois University School of Medicine, Springfield, Illinois, United States of America.|Simmons Cancer Institute at SIU, Post Office Box 19678, Springfield, Illinois 62794-9678, United States of America.
K Thomas
KT
Robbins
Division of Hematology and Oncology, Department of Internal Medicine, SIU, Springfield, Illinois, United States of America.|Department of ENT - Otolaryngology, SIU, Springfield, Illinois, United States of America.|Southern Illinois University School of Medicine, Springfield, Illinois, United States of America.|Simmons Cancer Institute at SIU, Post Office Box 19678, Springfield, Illinois 62794-9678, United States of America.
Aziz U
AU
Khan
Department of Medical Microbiology, Immunology and Cell Biology, SIU, Springfield, Illinois, United States of America.|Division of Hematology and Oncology, Department of Internal Medicine, SIU, Springfield, Illinois, United States of America.|Southern Illinois University School of Medicine, Springfield, Illinois, United States of America.|Simmons Cancer Institute at SIU, Post Office Box 19678, Springfield, Illinois 62794-9678, United States of America.
Krishna
K
Rao
D051927:CD24 Antigen / Q000096:biosynthesis*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis*
D051927:CD24 Antigen; C497889:CD24 protein, human; D009363:Neoplasm Proteins; D002945:Cisplatin